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Data mining and biological sample exportation from 
South Africa: A new wave of bioexploitation under the 
guise of clinical care?
In September 2015, the South African (SA) health 
insurer Discovery announced that, in partnership 
with Craig Venter’s company Human Longevity Inc., 
it would provide genetic testing to its members for 
USD250 (approximately ZAR3 400) per person. On 
the surface, this appears to be innovative and futuristic. However, a 
deeper look at this announcement reveals considerable problems in 
the exportation of biological samples and data out of SA, and brings 
into sharp focus the lack of protection in place for potential donors. 
In return for a reduced-cost genetic test, as part of that deal the 
deidentified information will be exported to and stored in Venter’s 
company in the USA.[1] It is possible that the data will be obtained 
from the samples in the USA, so the samples themselves will be 
exported. Genetic testing is being offered under the guise of clinical 
care, but for the apparent purpose of building up a large database for 
research in another country, and in so doing exposes the deficiencies 
of the SA regulatory framework on the use, storage and export of 
biological samples.
The data from these biological samples and the samples themselves 
are a valuable resource in medical research, helping to identify the 
roles that genes play in disease development and accelerating new 
drug development. For decades there has been a unidirectional 
flow of samples out of Africa to various destinations in developed 
countries, with no benefit to local populations or local researchers. 
Such ‘parachute research’ has impacted negatively on the development 
of local capacity, infrastructure and expertise. As genomic research 
is advancing in SA, every effort should be made to encourage its 
development and ensure that SA biological samples and data are 
used locally. International collaborations can further develop and 
improve local capacity, but this must be non-exploitative and involve 
a sharing of facilities, expertise and expense. A central feature of 
these collaborations often involves the sharing of samples and data 
among institutions within SA, across Africa and in the rest of the 
world. The H3Africa project, for example, seeks to make samples 
and data available among African collaborators for future research, 
necessitating the movement of samples across the H3Africa network. 
Central to this project is the importance of African leadership in the 
research, as well as strengthening control over the use of samples and 
data through its data and sample-sharing polices.[2,3]
However, this recent development by Discovery Health under-
mines the strengthening of African ownership of our samples 
and data, and is exactly the sort of exploitative behaviour that 
we must guard against. Although the relatively low cost of the 
genetic test offered by Discovery may be enticing, this exploits 
consumers and is reminiscent of safari research, as the data leave 
the country with no SA oversight or control, for the commercial 
benefit of a US company and Big Pharma. In a study involving 212 
participants in SA, almost 40% were not supportive of researchers 
or other organisations financially benefiting from the use of their 
biological samples, and 43% expressed a desire to share some of 
the profits.[4] However, the only benefit for Discovery members is 
the offering of a genetic test at a reduced rate that must come out 
of available day-to-day benefits. Discovery also promises access 
to genetic counselling, at a cost to be covered by the consumer.[5] 
This additional benefit is enticing. However, there are only 30 
genetic counsellors registered on the Health Professions Council 
of South Africa (HPCSA) register, of whom only 18 have a 
master’s degree in genetic counselling. Discovery has indicated 
that genetic counselling will be offered by doctors, yet very few 
doctors have training in this field and fewer still can afford to 
spend time on genetic counselling and consent processes in their 
busy consultation rooms.
Exome testing by Discovery demonstrates the need for guidelines 
and clarity in the export of biological data. The SA export permit 
system for tissues currently offers limited protection for tissue 
donors. The export of biological samples out of SA is governed by 
the National Health Act 2003, specifically the Regulations Relating 
to the Import and Export of Human Tissue, Blood, Blood Products, 
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Cultured Cells, Stem Cells, Embryos, Zygotes and Gametes 2012. [6] 
A biological sample cannot be exported without a valid export 
per mit, and only samples obtained under the terms of the Act 
can be exported. All applications must provide proof in writing 
that the biological sample will continue to be used within the 
terms of the Act once it is exported. The process requires that a 
register be established of all samples exported, thus ensuring that 
there is some oversight of the movement of samples out of SA. 
However, gaps in the regulations remain that must be addressed to 
protect the rights of participants as international collaborations are 
forged. Importantly, there is nothing in the regulations preventing 
Discovery from exporting the samples, unless an export permit is 
refused, and of concern is that there are no regulations overseeing 
the export of biological data from SA.
Export of biological samples:  
The consent concerns
Under the National Health Act 2003, informed consent is required 
for participation in medical research. Participants must be informed 
of the purpose of the research and any risks and benefit. Consent can 
then be given based on this information. Section 55 similarly requires 
the informed consent of the participant prior to the removal of any 
tissue. Biological samples can be reused and are a potential valuable 
resource for future research. Alternative consenting arrangements 
such as broad, tiered and dynamic consent have therefore been 
proposed. The 2015 Department of Health guidelines explicitly 
incorporate broad and tiered consent and provide guidance for 
research ethics committees (RECs).
The Organisation for Economic Co-operation and Development 
(OECD) guidelines on human biobanks require that all participants 
be informed of access to their sample, as well as transfer abroad. [7] 
The guidelines recommend REC approval for all future research, 
but the SA health research regulations are silent on consent that is 
required prior to the export of biological samples. It must simply be 
demonstrated that the sample was obtained within the parameters 
of the National Health Act 2003, i.e. that consent was obtained 
prior to its removal, and that it is to be used within the terms of the 
Act. The H3Africa informed consent guidelines state that one of its 
goals is to make samples widely available to facilitate research. This 
will include transferring samples abroad to collaborators. Yet in a 
review of 1 305 protocols submitted under the now repealed Human 
Tissues Act, it was found that fewer than 50% of the informed 
consent documents informed research participants of their intent 
to export samples. [8] Sample donors do not appear to be aware of 
the intent or indeed the possibility of the removal of their samples 
from the country, and RECs do not have a formal oversight role to 
play. Although it appears that samples and data will be exported 
under Discovery’s new scheme, the extent to which people who avail 
themselves of the test will be aware of the storage and use of their 
biological data is unclear.
Arguably broad consent could cover exportation of samples. 
Participants are consenting to the storage and reuse of their samples 
for future, unknown research, and this could cover research in 
another country. However, participants consent to the donation 
of their samples in accordance with the SA ethical and legal 
framework, and they can assume that the samples will be used in 
accordance with that framework. The right to withdraw samples 
is inherent in the process, but it may not be possible to exercise 
this right if samples are transferred abroad, as the sample will be 
used in accordance with the regulations of that country. Empirical 
evidence demonstrates that South Africans have clear preferences 
on the future use of their samples, including the exportation of the 
samples, and these preferences must be respected.[4] The possibility 
of exportation must therefore be raised during the informed consent 
process.
Considering the importance of the sharing of samples in genomic 
biobank research, it is surprising that the revised 2015 Department of 
Health guidelines are silent on the export of samples. At the very least 
it would be expected that RECs should have some oversight function. 
Once a sample is exported, the SA health research regulations 
and RECs lose all oversight and jurisdiction over the sample. Any 
assurances that the participant may have received in respect of 
storage, future use and confidentiality can no longer be guaranteed, 
and the REC has no power to prevent its use in future studies that 
are contrary to those views. In any case, it has no way of knowing 
for what research the samples are to be used, and it in effect loses 
control of the sample once it leaves the country. Upon adoption of the 
broad consent model, the REC is tasked with the role of gatekeeper 
of the samples, so it should be satisfied that the sample will be used 
within the terms of the consent prior to its exportation. However, 
by not requiring its approval, the regulations appear to circumvent 
the oversight function of RECs, a role that is invested in them by the 
national ethics guidelines.
The absence of a material transfer 
agreement (MTA)
The transfer of samples raises important ownership and intellectual 
property (IP) rights issues flowing from the sample. To resolve these 
issues in advance, exchanges of biological samples are generally 
conducted under the auspices of an MTA. An MTA is a legally 
binding agreement that documents the rights of the provider and 
recipient of the sample and is generally seen as facilitating the 
sharing of samples while offering protections to local institutions. [9] 
MTAs should describe the purpose of the transfer as well as any 
restrictions on the use of the sample. It may also stipulate the terms 
of any publication arising from the samples, ownership of the 
samples or new inventions from the samples, and any potential IP 
rights.[10]
Internationally, MTAs are a common feature of the transfer of 
samples endorsed by the OECD guidelines, the H3A High Level 
Principles on Ethics, Governance and Resource Sharing and the 
International Society for Biological and Environmental Repositories, 
among other organisations.[11] Considering the past exploitation of 
SA biological samples, it would be expected that an MTA be required 
under the SA regulatory system. However, this is surprisingly absent. 
The export permit system seems more concerned with tracking 
the movement of samples than protecting the rights of donors and 
research institutions in SA. The recently updated research ethics 
guidelines could have filled this vacuum and recommended the 
development of MTAs prior to transfer of samples. If not informed 
that their sample will be exported, donors will expect that their 
biological samples will be used in accordance with SA law. Health 
research regulations and guidelines differ across countries and may 
be lacking in some, so it cannot be guaranteed that the sample will be 
subject to the same protections.
Owing to the enforceability of the MTA, the provider of the sample 
can continue to exercise control over the sample, as stipulated in 
the MTA. Importantly, MTAs can also be used to enforce donor 
preferences, REC decisions and the protections of SA regulations on 
the use of the sample in other jurisdictions. It has also been suggested 
that RECs should have a role to play in ensuring that the terms of 
the MTA are in compliance with the local and national ethical 
guidelines.[12] The REC would need to approve the terms of the MTA 
and be satisfied about the future use of the sample, in light of the 
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original consent. This would also address some of the deficiencies in 
the consent process.
Although an MTA is likely to be a requirement of transfer of 
biological samples in most research institutions in SA, the lack of 
national guidance on this point leaves institutions with the task of 
creating MTAs that may not consider the important role that MTAs 
can have in protecting the rights of the donors. MTAs are generally 
seen as necessary to protect the intellectual property following from 
the sample, but they can also be valuable tools in protecting donor 
rights.
Exportation of data
Genomic biobanking research not only stores large quantities 
of biological samples but also generates considerable data, and 
Discovery’s announcement demonstrates the enormous commercial 
value of these data. Since the birth of the Human Genome 
Project, the focus has been on the release of data to promote the 
advancement of science through the Bermuda Principles of 1996 
and the Fort Lauderdale Agreement of 2003. Sharing of both 
samples and data is now often a condition of funding.[13] Yet the SA 
regulatory framework fails to address the complex issues involved 
in data sharing, illustrated by the Discovery development. It is 
primarily focused on consent, sample storage and sample reuse, 
requiring only that the confidentiality and privacy of donors are 
protected in the sharing of any data. Similar to the sharing of 
biological samples, the national ethics guidelines require REC 
approval prior to the sharing of data, but with no requirement to 
consult the REC in advance of exportation of the data, it is not clear 
whether this is taking place. The announcement from Discovery 
does not provide any indication of ethical approval or oversight, 
and this should be guarded against.
Unlike the samples themselves, data are not physically exported 
and would therefore not form part of the export permit system. 
However, it is possible for the sample to remain in SA but for the 
data arising from that sample to be exported, as may be in the case 
in Discovery’s new initiative, necessitating the need for oversight on 
the access to data. Confidentiality and privacy of participants must be 
assured, and there should be oversight of data transfer. The Protection 
of Personal Information Act 2013 does strive to offer protection on 
the use of data, and it requires a binding contract (such as an MTA) 
and the consent of the donor prior to exportation. However, the Act 
only covers biometric data; this does include DNA, but it is not clear 
whether other types of data flowing from biological samples are 
covered.
The HPCSA has addressed this point, and its guidelines state:
‘There must be justifiable reasons which should be provided to 
Research Ethics Committees for data and specimens to leave 
the country. This should only be done after a Material Transfer 
Agreement has been signed and submitted to the local Research 
Ethics Committee.’[14]
These guidelines pertain only to healthcare professionals in SA 
who are registered with the Council, and not to the wider scientific 
community. However, the protection of data is just as important as the 
samples themselves. REC oversight is necessary, and the requirement 
of an MTA or data transfer agreement should be a feature of the SA 
regulatory framework.
Conclusion
To protect the genomic heritage of the country, proper national 
oversight on the exportation of biological samples is necessary. 
Medical insurance companies should not be permitted to exploit SA 
genetic heritage, yet the existing export permit system provides little 
in the way of ethical oversight and is more concerned with keeping 
a register of the movement of samples than ensuring that the system 
protects the rights of participants. Other than the requirement that 
the donor consents to the donation of the sample, it appears that there 
is no requirement for donor consent or REC consent for export. The 
export permit system fails to consider the need for legal and ethical 
oversight of the preferences of donors on the use of either their sample 
or the rights arising out of the future use of the sample.
Public trust is crucial to the success of biobank research, and the 
removal of biological samples in the absence of any oversight as specified 
in the consent document may be an invasion of that trust. Equally, data 
should not be removed in this way. In an effort to have a public account 
of the movement of the samples, considerable gaps remain within the 
SA export permit system. Currently it offers no ethical oversight of the 
transfer of the samples and data, and the protection of local researchers 
is not required by law. International collaborative research raises specific 
ethical concerns, particularly when collaborators are from high-income 
countries. Such collaborations should be allowed to flourish and can be 
of considerable benefit to SA researchers, but they must not be at the 
expense of the local researcher, and our regulatory framework must 
protect the rights of both the donor and the researcher.
However, a revision of the 2012 regulations is not necessary to fill 
the vacuums identified here. Rather they could be addressed on a 
national code of practice governing the use, reuse and exportation of 
biological samples that requires ethical approval and an MTA prior 
to the removal of samples, and that exportation of samples should be 
raised during the informed consent process. In the interim, MTAs can 
fill the gap left by the regulations and stipulate that the sample and 
data are used in accordance with national ethics guidelines and the 
terms of the original consent.
C Staunton, K Moodley
Centre for Medical Ethics and Law, Faculty of Medicine and Health 
Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa
Corresponding author: C Staunton (ciarastaunton@sun.ac.za)
1. Cassidy S. Discovery to offer genetic testing. http://www.iol.co.za/lifestyle/discovery-to-offer-genetic-
testing-1.1920337#.VhJuuCvd2y5 (accessed 20 October 2015).
2. H3Africa High Level Principles on Ethics, Governance and Resource Sharing. http://h3africa.org/
about/ethics-and-governance (accessed 6 January 2016).
3. Ramsay M. Growing genomic research on the African continent: The H3Africa Consortium. S Afr Med 
J 2015;105(12):1016-1017. [http://dx.doi.org/10.7196/SAMJ.2015.v105i12.10281]
4. Moodley K, Sibanda N, February K, Rossouw T. ‘It’s my blood’: Ethical complexities in the use, storage 
and export of biological samples: Perspectives from South African research participants. BMC Med 
Ethics 2014;15:4. [http://dx.doi.org/10.1186/1472-6939-15-4]
5. Discovery. Product enhancement in 2016. https://www.discovery.co.za/portal/individual/medical-aid-
news-product-enhancements-2016 (accessed 6 January 2016).
6. http://www.sashg.org/documents/GovGazette2Mar2012.pdf (accessed 6 January 2016).
7. OECD Guidelines on Human Biobanks and Genetic Research Databases 2009. http://www.oecd.org/
sti/biotech/44054609.pdf (accessed 20 October 2015).
8. Sathar A, Dhai A, van der Linder S. Collaborative international research: Ethical and regulatory issues 
pertaining to human biological materials at a South African institutional research ethics committee. 
Dev World Bioeth 2014;14(3):150-157. [http://dx.doi.org/10.1111/dewb.12018]
9. Ramsay MJ, de Vries J, Soodyall H, Norris S, Sankoh O. Ethical issues in genomic research on the 
African continent: Experiences and challenges to ethics review committees Human Genomics
2014;8(15). [http://dx.doi.org/10.1186/s40246-014-0015-x]
10. Rodriguez V. Material transfer agreements: Open science vs. proprietary claims. Nat Biotechnol
2005;23(4):489-491. [http://dx.doi.org/10.1038/nbt0405-489]
11. International Society for Biological and Environmental Repositories. Best Practices for Repositories: 
Collection, Storage, Retrieval and Distribution of Biological Materials for Research. 3rd ed., 2011.
Biopreserv Biobank 2012;10(2):81-161.
12. Chalmers D, Nicol D, Nicolas P, Zeps N. A role for research ethics committees in exchanges of human 
biospecimens through material transfer agreements. J Bioeth Inq 2014;11(3):301-306. [http://dx.doi.
org/10.1007/s11673-014-9552-1]
13. Knoppers BM, Harris J, Tasse AM, et al. Towards a data sharing code of conduct for international 
genomic research. Genome Med 2011;3:46. [http://dx.doi.org/10.1186/gm262]
14. Health Professions Council of South Africa. Ethical Guidelines for Good Practice in the Health Care 
Professions: General Ethical Guidelines for Health Researchers. Book 6. http://www.hpcsa.co.za/
Uploads/editor/UserFiles/downloads/conduct_ethics/rules/generic_ethical_rules/booklet_6_gen_
ethical_guidelines_for_researchers.pdf (accessed 17 October 2014).
S Afr Med J 2016;106(2):136-138. DOI:10.7196/SAMJ.2016.v106i2.10248
